The Molecular Imaging Program (MIP) consists of 19 members from 7 different departments. Since the last funding cycle the research base of the Program increased 46% from $5,740,595 total annual direct research support, of which $6,393,909 Is from the NCI. Over this last grant period, there were 188 publications of the Molecular Imaging Program, of which 28,7% were intra-programmatic and 36,7% were inter-programmatic. The program has made significant advances in developing novel technologies that facilitate diagnosis and treatment of cancer, and also has provided methodologies and reagents wherein the efficacy of various therapeutics can be monitored in real-time in pre-clinical and clinical settings. These advances include the development of novel molecular Imaging reporter molecules which have Improved our understanding of cancer etiology, biology, pathophysiology and therapy. We will continue to develop cutting edge approaches for imaging the presence of pre-malignant (dysplastic) tissue and oncogenic signaling molecules in vivo. We have developed an Integrated optical molecular Imaging strategy that uses fluorescence peptides as probes to target the presence of pre-malignant (dysplastic) tissue in vivo. The recruitment of Thomas Wang MD, PhD from Stanford University provides the MIP with new capabilities, especially the development of novel optical Imaging probes and instrumentation that can be used as a diagnostic cancer screen for early detection in variousorgans. Drs Ross, Rehemtulla and Luker will continue to develop and validate molecular imaging reporters (i.e. CXCR, c-Met and Akt), Non-invasive imaging in cells and animals will be used to evaluate these novel reporter constructs for detection of key oncogenic signaling pathways. These tools and concepts should significantly aid in our preclinical drug development process and provide insights into more efficacious combination therapy strategies for tumors. Drs Ross, Meyer and Chenevert will continue to develop novel MR-imaging based surrogates for quantification of early therapeutic efficacy in cancer patients. Recent breakthroughs in this area include the concept that analysis of changes within individual voxels (parametric response mapping, PRM) over time, provide a much more robust and predictive quantitative measure of treatment response than current approaches. Application of the PRM concept to clinical trials in brain, breast, head and neck as well as in prostate cancer metastatic to bone, have yielded results that demonstrate the early predictive power of MR-imaging especially when combined with PRM analysis.

Public Health Relevance

A wide variety of molecular imaging techniques are under active investigation &have great potential to noninvasively provide never before available quantitative information re: physiologic and biological properties of tumors at the molecular and systemic levels unavailable from routine structural Imaging techniques alone. These techniques enhance the efficiency of cancer diagnosis, treatment as well as oncologic research. The ability to assess tumor response to therapy positively impacts those with cancer as will recent developments in early detection and staging.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046592-24
Application #
8300273
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-06-01
Project End
2017-05-31
Budget Start
2012-09-21
Budget End
2013-05-31
Support Year
24
Fiscal Year
2012
Total Cost
$49,605
Indirect Cost
$17,685
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Schofield, Heather K; Zeller, Jörg; Espinoza, Carlos et al. (2018) Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight 3:
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Stoffel, Elena M; Koeppe, Erika; Everett, Jessica et al. (2018) Germline Genetic Features of Young Individuals With Colorectal Cancer. Gastroenterology 154:897-905.e1
Djuric, Zora; Bassis, Christine M; Plegue, Melissa A et al. (2018) Colonic Mucosal Bacteria Are Associated with Inter-Individual Variability in Serum Carotenoid Concentrations. J Acad Nutr Diet 118:606-616.e3
Mann, Jacqueline E; Smith, Joshua D; Birkeland, Andrew C et al. (2018) Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. Cancer Immunol Immunother :
Jiagge, Evelyn; Jibril, Aisha Souleiman; Davis, Melissa et al. (2018) Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations. J Glob Oncol :1-8
Bowers, Emily; Slaughter, Anastasiya; Frenette, Paul S et al. (2018) Granulocyte-derived TNF? promotes vascular and hematopoietic regeneration in the bone marrow. Nat Med 24:95-102
Holt, Melissa C; Assar, Zahra; Beheshti Zavareh, Reza et al. (2018) Biochemical Characterization and Structure-Based Mutational Analysis Provide Insight into the Binding and Mechanism of Action of Novel Aspartate Aminotransferase Inhibitors. Biochemistry 57:6604-6614
Wang, Yin; Day, Mark L; Simeone, Diane M et al. (2018) 3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer. J Vis Exp :

Showing the most recent 10 out of 1493 publications